0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aida Pharmaceuticals
Its shares trade under the ticker AIDA. It has been listed since 5 July 2006. In the fiscal year to 31 December 2007, it reported revenue of $29.2m and net income of $2.7m. At that date it held total assets of $62.7m and shareholders' equity of $13.3m.
AiDa Pharmaceuticals, Inc. engages in the development, production, and distribution of pharmaceutical products. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2006-07-05. Earjoy is an investment holding company. Hangzhou Aida is a pharmaceutical company engaged in the development, manufacture, marketing, licensing, and distribution of pharmaceutical products primarily in mainland China. Hangzhou Aida has a total of nine production lines for the manufacture of antibiotics, cardiovascular and anti-tumor drugs in various forms, including injectable powder, injectable liquid, capsules, tablets and ointments. Hangzhou Aida’s primary product is the injectable powder form of Etimicin Sulfate.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 5 Jul 2006
- Employees
- 450
- Website
- babyken.a32.53dns.com ↗
Leadership
Pay as last reported
- Biao JinChairman of the Board, Chief Executive Officer$19,056
- Hui LinChief Financial Officer$12,704
- Yuejun JiangSecretary
- Jiajun QiuDirector
- Qiong ZhangDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Aida Pharmaceuticals Inc holds a strong market position in the pharmaceutical industry. The company has established itself as a trusted brand, providing high-quality medications and healthcare products to consumers.
- Aida Pharmaceuticals Inc heavily invests in research and development, fostering innovation and enabling the company to continuously introduce new and effective drugs to the market. This leads to a competitive edge and strengthens its product portfolio.
- Aida Pharmaceuticals Inc has a widespread global presence, allowing it to reach a diverse range of markets and expand its customer base. This international footprint provides opportunities for growth and revenue generation.
Weaknesses
- Aida Pharmaceuticals Inc relies heavily on third-party suppliers for raw materials and ingredients. Any disruption in the supply chain can adversely affect production and lead to delays in delivering products to customers.
- Despite its strong market position, Aida Pharmaceuticals Inc faces challenges in building widespread brand recognition. This can limit its ability to attract new customers and compete effectively with more well-established pharmaceutical companies.
Opportunities
- Aida Pharmaceuticals Inc can explore opportunities in emerging markets where the demand for pharmaceutical products is increasing. By expanding its operations into these markets, the company can tap into new customer segments and drive growth.
- With the rapid advancements in technology, Aida Pharmaceuticals Inc can leverage innovative solutions in drug development, manufacturing, and distribution. This can enhance operational efficiency and enable the company to stay ahead of competitors.
Threats
- The pharmaceutical industry is highly competitive, with numerous players vying for market share. Aida Pharmaceuticals Inc faces the threat of intense competition from both established companies and new entrants, which can impact its market position and profitability.
- Aida Pharmaceuticals Inc operates within a heavily regulated industry. Compliance with strict regulations and evolving regulatory frameworks poses challenges and can lead to additional costs, delays, and potential legal issues.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.